Approximately 17% of the 1 million cases of breast cancer diagnosed annually worldwide are of the triple-negative (oestrogen receptor– (ER-)/progesterone receptor– (PR-)/HER2-negative) phenotype1. Here, PGR is linked to breast carcinoma.